1Sander GE, Mckinnie JJ, Greenberg SS et al, Angiotensin-conerting enzyme inhibiters and angiotensin Ⅱ receptor antagonists in the treatment of heart failure caused by left vantricular systolic dysfunction. Prog Cardiovase Dis,1999141(4):265～300
2Inada y. Ojima M, Kanngawa K et al. Pharmacologic properties of candesartan eilexetil-possible mechanisms of long-acting antihypertensive action. J Hum Hypertens,1999;12(suppl 1):S75～S80
3Burnier M, Brunner HR. Comparative antihypertensive effects of angiotensin Ⅱ receptor antagonists. J Am Soc Nephrol,1999;10 (Suppll2):S278～S282
4Meredith PA. Optimal dosing characteristics of the angiotensin Ⅱ receptor antagonist telmisartan. Am J Cardiol, 1999;84(2A):7K～I2K
5Kirk JK. Angiotensin Ⅱ receptor antagonists: their place in therapy. Am Fam Physician,1999,59(ll):3140～3148
6Leeuw PW. How do angiotensin Ⅱ receptor antagonsts affect bllood pressure? Am J CardioL1999;84(2A):5K～6K
7Brown NJ, Agirbasli M, Vanghan DE. Comparative effect of angiotensin-converting enzyme inhibition and angiotenain Ⅱ type Ⅰreceptor antagonism on plasma fibrinolytic balance in humans. Hypertension, 1999;34(2):285～290
8Wilmink HW, Banga ID, Hijmering M et al. Effect of angiotensin-converting enzyme inhibition and angiotensin Ⅱ type Ⅰreceptor antagonism on post prandial endothelial, function, J Am Coll Cardiol, 1999;34(1): 40～145
9Brooks DP, Ohlstein EH. Ruffolo RR Pharmacology of eprosartan an angiotensin Ⅱ receptor antagonist: exploring hypotheses from clinical data. Am Heart J, 1999,138(3 pt 2):246～251
10Shusterman NH. Safety and efficacy of eprosartan, a new angiotensin Ⅱ receptor blocker Am Heart J, 1999;138(3 pt 2):238～245
